BC is the most common female malignancy worldwide [1], with ERα positivity accounting for more than 70% of all diagnoses [34] and tamoxifen still representing the mainstay of treatment and prevention for this BC subtype [35]. This evidence concerns the gene ESR1 and breast cancer.